Combining the impacts of anlotinib on the tumor immune microenvironment and intra-tumor accumulation of the anti-PD-L1 antibody, we next assessed the therapeutic effects of treatment with anlotinib plus anti-PD-L1 antibody in the 4T1 tumor model. This evidence concerns the gene CD274 and neoplasm.